Humanetics Executive and Leadership Team

Amit Singhi, the Chief Financial Officer at Humanetics, directs all financial operations and strategic fiscal planning. Singhi oversees budgeting, forecasting, and resource allocation, ensuring robust financial health for the company's clinical-stage drug development programs. This leadership role involves managing investor relations and securing capital essential for advancing proprietary drugs in markets with urgent and unmet needs. By optimizing financial strategies, Amit Singhi directly supports the accelerated discovery and commercialization efforts, particularly in medical countermeasures and radiation modulators for oncology and inflammatory lung diseases. The Chief Financial Officer's oversight extends to financial compliance and risk management, safeguarding the company's assets and ensuring sustainable growth. Singhi's expertise is critical for navigating the complex financial landscape of pharmaceutical development and maximizing shareholder value.

Barnaby Loehnis, the President, Humanetics Sensors at Humanetics, spearheads the strategic direction and operational execution for the sensors division. Loehnis drives innovation and market penetration for sensor technologies, crucial for the company's broader pharmaceutical development goals. This executive role involves fostering cross-functional collaboration between the sensors unit and the drug discovery teams, ensuring technological advancements align with clinical needs. By overseeing product development and market strategy, Barnaby Loehnis enhances the company's competitive edge in developing medical countermeasures. The President, Humanetics Sensors is responsible for expanding the division's capabilities and ensuring its contribution to addressing urgent and unmet needs in oncology and inflammatory lung diseases. Loehnis's leadership ensures the seamless integration of advanced sensor technology into the company's research and commercialization pipeline.

Barney Loehnis, the President, Humanetics Sensors at Humanetics, directs the strategic growth and operational efficiency of the sensors business unit. Loehnis focuses on developing and deploying cutting-edge sensor solutions that support the company's mission in medical countermeasures and radiation modulators. This leadership position involves managing key partnerships and driving technological innovation to meet the demands of clinical-stage pharmaceutical development. By ensuring the highest standards of quality and performance, Barney Loehnis contributes significantly to the company's ability to address urgent and unmet needs. The President, Humanetics Sensors oversees research and development initiatives, aiming to enhance diagnostic and therapeutic capabilities. Loehnis's strategic oversight is vital for the successful integration of sensor technology into the company's pipeline for oncology and inflammatory lung diseases.

Karsten Newbury, the President, Humanetics Digital at Humanetics, leads the digital transformation and technological integration across the organization. Newbury drives the development and implementation of digital strategies that accelerate drug discovery and enhance commercialization efforts. This executive function involves overseeing data analytics, AI integration, and digital platforms essential for advancing proprietary drugs in markets with urgent and unmet needs. By optimizing digital workflows, Karsten Newbury ensures efficient operations for medical countermeasures and radiation modulators targeting oncology and inflammatory lung diseases. The President, Humanetics Digital is responsible for leveraging technology to improve research outcomes and patient engagement. Newbury's expertise is critical for building a robust digital infrastructure that supports the company's long-term growth and innovation in pharmaceutical development.